Treatment & Research Achievements

Treatment & Research Achievements


Bladder Cancer

Year Contributions in Treatment and Research
1943-1949 Techniques of Radical Cystectomy and Pelvic Lymphadenectomy
1952 Myron Melamed Describes Carcinoma-In-Situ of the Urothelium
1956 Technique of Urethrectomy
1959 Preoperative Irradiation and Radical Cystectomy
1973 Technique of In-Continuity Urethrectomy during Radical Cystectomy
1974 Outpatient Cystoscopy and Fulguration of Recurrent Superficial Papillary Bladder Tumors
1975 Identification and Characterization of Tumor-Associated Antigens
1979 Diagnostic Value of Urinary Cytology and Flow Cytometry
1979-1984 Intravesical Bacillus Calmette-Guérin (BCG) for Superficial Bladder Tumors and Randomized Trials of BCG, used for FDA Approval
1981 Ureteroscopic Destruction of Upper Tract Tumors
1983 Neoadjuvant MVAC Chemotherapy and Radical Cystectomy
1983-1992 MVAC Chemotherapy Cures Transitional Cell Carcinoma
1983-1995 Bladder-Sparing Strategies for Invasive Bladder Cancer
1989 Prognostic Significance of Lewis Blood Group Antigen

G-CSF Effective with M-VAC Chemotherapy

Prognostic Factors Identified
1992-1999 Molecular Analysis (Rb, p53, mdm22, p16, p21, INK4A)
1995-1999 ITP Chemotherapy Improves Survival, and Post-Chemotherapy Surgery Found Beneficial
1997 New Staging for Bladder Cancer (Generated by Memorial Sloan Kettering’s Urology Service and Department of Pathology) Adopted by AJCC/UICC

Defined Survival Benefit Related to the Quality of the Pelvic Lymph Node

Dissection in Patients Undergoing Radical Cystectomy

Defined Refractory Carcinoma-In-Situ
2006 Established an Outcomes Nomogram for Bladder Cancer Patients Undergoing Radical Cystectomy
2007-2009 Described the Treatment Paradigm Shift in Management of T1 Bladder Cancer
2008 Established Pathologic Concerns for Prostate-Sparing Radical Cystectomy
Helped to Establish Role of Gemcitabine and Cisplatin in the Neoadjuvant Management of Muscle-Invasive Bladder Cancer
2009 Comprehensively Established Morbidity Associated with Radical Cystectomy and Urinary Diversion
2010 Documented Role of Minimally Invasive Surgical Techniques in the Management of Upper Tract Transitional Cell Carcinoma
2012 Established the Genomic Characteristics of Bladder Cancer That Will Allow for Targeting Therapy More Effectively in Bladder Cancer Patients
Data Validating Updated TNM Staging of LN for Bladder Cancer Patients

Prostate Cancer

Year Contributions in Treatment and Research
1950-1960 Ablative Surgery
Exenteration for Locoregional Cancers
1970 Whitmore Staging System (AJCC)
Technique of Retropubic I-125 Implantation
Natural History Defined
1974 Flutamide
1993 Prostate-Specific Monoclonal Antibodies (PSMA)
Cloning of PSMA Gene
Neoadjuvant Hormonal Therapy and Radical Prostatectomy
Three-Dimensional Conformal Radiation Therapy with Intensity Modulation
1995 Flutamide Withdrawal Syndrome
1999 Prognostic Nomograms
Nerve Grafts with Radical Prostatectomy
Quality of Life, Utility Assessment
2004-2006 Surgeon as an Independent Predictor of Outcomes
2007-2010 Describe Surgical Learning Curve for Radical Prostatectomy
2007-2012 Established Indications for Standard vs Limited Pelvic Lymph Node Dissection
2010 Completed First Comprehensive Genomic Analysis of Prostate Cancer Comprising a Wide Spectrum of the Disease across Multiple Platforms

Testis Cancer

Year Contributions in Treatment and Research
1960 Technique of Retroperitoneal Lymph Node Dissection
1972-7980 Cisplatin-Based Combination Chemotherapy
VAB-I through VAB-VI Protocols
Hydration for High-Dose Cisplatin Chemotherapy
Salvage Surgery Post-Chemotherapy
Adjuvant Chemotherapy
1979 Surveillance for Stage I Nonseminomatous Germ Cell Testis Tumors
1983 Risk-Adjusted Treatment Strategies
Salvage Chemotherapies
1988 Marker Gene I(12)p
1997 Staging System Incorporating Tumor Markers Defined
Mechanism of TP53 Mutations and Resistance
1998 Management of Teratoma with Secondary Somatic Malignancy
2000 TIP for Second-Line Chemotherapy
2003 Integration of Markers Status in  Clinical Decision Making for Patients with Low-Stage Non-Seminomatous Germ Cell Testis Tumors
2007 High-Dose TICE for Salvage Chemotherapy
2007 Implications of Modified Templates in Low-Stage and Advanced Non-Seminomatous Germ Cell Testis Tumors — Bilateral Infrahilar Is the Gold Standard
2009 Nerve-Sparing Retroperitoneal Lymph Node Dissection following Chemotherapy
2010 Impact of Total Number of Lymph Nodes Resected on Clinical Outcome
2021 First CLIA and State Department of Health (NY) Approval for MSK miRNA Assay (MMA)
2022 Full accrual of “TIGER” Trial (High-Dose Chemotherapy vs TIP)

Renal Cancer

Year Contributions in Treatment and Research
1949 Technique of Radical Nephrectomy
1975 Tumor Vaccine Developed
Monoclonal Antibodies
1979 Partial Nephrectomy in Patients with Normal Contralateral Kidney
1997 Histologic and Molecular Genetic Classification
1998 Randomized Trials of Cis-Retinoic Acid ± Interferon 
1997-2000 Prognostic Factors and Nomogram
2006 Partial Nephrectomy Prevents Chronic Kidney Disease
2007-2012 Establishment of Clear Cell Renal Carcinoma-Specific ImmunoPET Scan (G250)

Penile and Urethral Cancer

Year Contributions in Treatment and Research
1956 Technique of Radical Groin Dissection
1983 Extended Radical Excision (Pubectomy, Emasculation)
1994 Described Myocutaneous Flap Coverage following Massive Groin Dissection with Skin Loss
1996 Risk Stratification for Invasive Penile Cancer
2001 Management of Genitourinary Melanoma Described
2006 Sentinel Lymphoscintigraphy Utilized in Penile Carcinoma and Melanoma